Thrombocytopenia and Associated Factors Among HIV Infected Patients in Pre- and Post-Anti-Retroviral Therapy, North East Ethiopia

Figures & data

Table 1 Socio-Demographic and Clinical Characteristics of HIV-Positive Patients Taking ART at DBRH, North-East Ethiopia, 2020

Variables	Frequency	Percentage
Age in years
18–29	34	12.5
30–39	97	35.9
40–49	82	30.0
≥50	59	21.6
Sex
Male	110	40.4
Female	162	59.6
Marital status
Single	23	49.8
Divorced	39	27.5
Married	135	8.4
Widowed	75	14.3
Educational status
Illiterate	74	27.1
Primary school	92	33.7
High school	63	23.1
Certificate and above	44	16.1
WHO clinical stages
Stage I	144	52.9
Stage II	36	13.2
Stage III	87	31.9
Stage IV	5	1.8
Types of ART regimen
1c	14	5.1
1d	10	3.7
1e	75	27.6
1j	130	47.8
2f	19	7.0
2h	18	6.6
Not registered	6	2.2

Notes: 1c = AZT-3TC-NVP, 1d = AZT-3TC-EFV, 1e = TDF-3TC-EFV, 1f = TDF-3TC-NVP, 1j = TDF-3TC-DTG, 2f = AZT-3TC-ATV/r, 2h = TDF-3TC-ATV/r.

Table 2 Thrombocytopenia and Associated Factors in Pre-ART HIV-Infected Patients Attending DBRH, North –East Ethiopia, 2020

Variables	Thrombocytopenia		COR	AOR	P-value
	Yes (%)	No (%)
Age in groups
18–29	8(23.5%)	26(76.5%)	1.32(0.49–3.48)	1.22(0.44–3.36)	0.28
30–39	15(15.3%)	83(84.7%)	2.24(1.02–4.92)	1.93(0.84–4.44)
40–49	22(26.8%)	60(73.2%)	1.1(0.52–2.32)	0.94(0.43–2.07)
≥50	17(28.8%)	42(71.2%)	1	1
Sex
Male	30(27.3%)	80(72.7%)	0.63(0.36–1.12)	0.74(0.4–1.38)	0.35
Female	31(19.1%)	131(80.9%)	1	1
WHO clinical stages
Stages I & II	34(18.8%)	147(81.2%)	1.89(1.1–3.38)	1.58(0.84–2.95)	0.15
Stages III & IV	28(30.4%)	64(69.6%)	1	1
CD4 counts (cells/µL
<200	41(35.0%)	76(65.0%)	0.33(0.16–0.69)	0.42(0.18–0.92)	0.04
200–349	10(12.0%)	73(88.0%)	1.29(0.52–3.25)	1.42(0.55–3.67)
≥350	11(15.1%)	62(84.9%)		1

Figure 1 Degree of thrombocytopenia among HIV-infected patients on ART in DBRH, North-East Ethiopia.

Table 3 Thrombocytopenia and Associated Factors in HIV-Infected Patients on ART Attending DBRH, North –East Ethiopia, 2020

Variables	Thrombocytopenia		COR	AOR	P-value
	Yes (%)	No (%)
Age in groups
18–29	4(11.8%)	30(88.2%)	1.35(0.38–4.77)	1.35(0.38–4.79)	0.86
30–39	16(16.3%)	82(83.7%)	0.92(0.38–2.25)	0.87(0.36–2.13)
40–49	11(13.6%)	70(86.4%)	1.15(0.44–2.97)	1.15(0.44–3.03)
≥50	9(15.3%)	50(84.7%)	1	1
Sex
Male	18(16.5%)	91(83.5%)	0.79(0.4–1.56)	0.79(0.39–1.58)	0.49
Female	22(13.6%)	140(86.4%)		1
ART regimen
AZT based	7(16.3%)	36(83.7%)	0.89(0.37–2.12)	0.88(0.35–2.21)	0.79
TDF based	33(14.8%)	190(85.2%)	1
CD4 counts (cells/µL
<200	2(15.4%)	11(84.6%)	0.97(0.21–4.65)	0.96(0.19–4.78)	0.86
200–349	5(11.9%)	37(88.1%)	1.33(−0.49–3.63)	1.34(0.47–3.79)
≥350	33(15.2%)	184(84.8%)	1